| 摘要 |
The present disclosure relates generally to methods for treating progressive neurodegenerative diseases, including their progressive forms. In particular, the present disclosure pertains to methods of treating or preventing progressive neurodegenerative diseases, including their progressive forms and its associated symptoms by administration of a combination of geranylgeranylacetone (teprenone), ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine), and riluzole (insert chemical name?), or pharmaceutically acceptable salts thereof. |
